Michael Hunkapiller, Ph.D.Chairman, CEO & President
Michael Hunkapiller became President & CEO of Pacific Biosciences in 2012. He is Chairman of PacBio’s Board of Directors, and has served on the Board since 2005. Dr. Hunkapiller spent over 30 years of his career helping build Applied Biosystems (“ABI,” now part of Thermo Fisher Scientific Inc.) into a market leader in the life sciences industry. From 1995 to 2004, he served as ABI’s President and General Manager. In 2004, he joined Alloy Ventures as a General Partner, and in 2005 led Alloy’s investment in PacBio. Dr. Hunkapiller continues to represent Alloy Ventures as a Director of NuGEN Technologies Inc.
During his term at ABI, Dr. Hunkapiller developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI’s sister company, Celera Genomics, and Senior Vice President of Applera Corporation (Celera’s parent company).
Prior to joining ABI, Dr. Hunkapiller was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two-dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.Chairman of the Board
Susan K. BarnesSenior Vice President and Chief Financial Officer
Susan K. Barnes joined PacBio in February 2010 with nearly 30 years’ experience in senior financial management. From 1997 to 2005, she was Senior Vice President, Finance and Chief Financial Officer of Intuitive Surgical, Inc. Ms. Barnes started at Intuitive Surgical as its first full-time finance person during the company's early development stages, and retired when it was a public company with a market capitalization of more than $3 billion and positive cash flow of more than $50 million a year. From 1994 to 1996, Ms. Barnes was Managing Director of the Private Equity Group at Jefferies & Company. From 1991 to 1994, she was Chief Financial Officer and Managing Director of Richard C. Blum and Associates, a merchant banking company with more than $500 million in funds under management. From 1985 to 1991, she served as Vice President and Chief Financial Officer of NeXT Computer, Inc., a company she helped start with Steve Jobs after serving as Controller of the Macintosh Division at Apple Computer from 1981-1985.
In addition to her role at Pacific Biosciences, Ms. Barnes sits on the Boards of Trustees for Bryn Mawr College and The Nueva School in Hillsborough, CA.
Ms. Barnes received an A.B. from Bryn Mawr College and an M.B.A from the Wharton School, University of Pennsylvania.
Kevin CorcoranSenior Vice President, Market Development
Kevin Corcoran has more than 27 years of experience in the life sciences industry. Prior to joining Pacific Biosciences, Mr. Corcoran served as President and CEO of Lynx Therapeutics from 2002-2004 where he was responsible for the development and commercialization of a massive parallel short ready sequencing technology – MPSS. While at Lynx, Mr. Corcoran jointly acquired with Solexa management the DNA cluster amplification technology, which is now a key component of Illumina’s sequencing platforms. From 2004-2007, Mr. Corcoran served as Vice President and General Manager of Applied Biosystems DNA sequencing business, a global business with over $600M dollars in annual sales.
Mr. Corcoran joined Pacific Biosciences in 2007 as Vice President of software and informatics development and subsequently was promoted to Senior Vice President responsible for all systems related development for the PacBio RS II System. Currently Mr. Corcoran is responsible for all marketing related activities and customer support functions.
Mr. Corcoran holds a B.S. in Computer Science from California State University, Hayward.
Jonas Korlach Ph.D.Chief Scientific Officer
Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company’s eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University.
Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator “Champion of Change.” He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.
Kathy OrdoñezChief Commercial Officer and Executive Vice President
Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. From January 2012 until June 2013, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics Inc., a leading provider of diagnostic information services, where she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation, a leading provider of genetic testing products for HIV resistance, Cystic Fibrosis and high complexity tissue transplantation, in 2011. From April 2002 until May 2011, Ms. Ordoñez was the Chief Executive Officer at Celera and she founded Celera Diagnostics in December 2000. From 1985 until 2000, Ms. Ordoñez held several senior positions at Hoffmann- La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields. Ms. Ordoñez also served as Director, non-Executive Chairman, and Chief Executive Officer of RainDance Technologies, Inc., which was sold to Bio-Rad Laboratories, Inc. in February 2017.Independent Director
Michael PhillipsSenior Vice President Research and Development
Mr. Phillips joined Pacific Biosciences in 2005 to direct development of the company's technology. Mr. Phillips has 20 years’ experience in diverse leadership and management roles spanning R&D, test, manufacturing operations, and service support at Applied Biosystems. He was in charge of developing some of Applied Biosystems most critical products within the company's genetic analysis, real-time PCR and microarray R&D business groups. Mr. Phillips managed a diverse team to drive new products to successful introduction. Mr. Phillips' previous experience includes working in the Immunoassay R&D group at Hyland Laboratories and the National Marine Fisheries Service. Mr. Phillips holds a BS in Bacteriology from U.C. Davis.
Stephen Turner Ph.D.Chief Technology Officer
Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and in 2004 secured its Series A funding. He was awarded a Ph.D. in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. He was a member of the project team at Cornell which developed the technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner's undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of Science in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 50 scientific papers in fields ranging from DNA sequencing technology and biophysics to genomics and epigenomics. He is listed as the inventor on over 50 U.S. patents and numerous published patent applications. Dr. Turner was recipient of the MIT Technology Review "TR100" Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008.